STOCK TITAN

Gracell Biotechnologies Inc - GRCL STOCK NEWS

Welcome to our dedicated news page for Gracell Biotechnologies (Ticker: GRCL), a resource for investors and traders seeking the latest updates and insights on Gracell Biotechnologies.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Gracell Biotechnologies's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Gracell Biotechnologies's position in the market.

Rhea-AI Summary
Gracell Biotechnologies Inc. announced its acquisition by AstraZeneca, ceasing to be a publicly traded company. Shareholders will receive $2.00 per share in cash and one contingent value right per share. The deal includes a milestone payment of $0.30 per CVR upon achievement. ADS holders will receive $10.00 per ADS and five CVRs per ADS. Warrants to purchase shares will be cancelled. The company will delist from Nasdaq and suspend reporting obligations under the Securities Exchange Act of 1934.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
acquisition
-
Rhea-AI Summary
Gracell Biotechnologies Inc. shareholders have approved the Agreement and Plan of Merger with AstraZeneca Treasury Limited and Grey Wolf Merger Sub, leading to Gracell becoming a private company and delisting from the Nasdaq Global Select Market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.04%
Tags
acquisition
-
Rhea-AI Summary
Gracell Biotechnologies Inc. announced that the U.S. FDA has cleared its Investigational New Drug (IND) application, allowing the Company to initiate a Phase 1 clinical trial of GC012F in the United States for the early-line treatment of multiple myeloma (ELMM). GC012F is an autologous CAR-T therapeutic candidate dual-targeting B cell maturation antigen (BCMA) and CD19 and utilizes Gracell’s proprietary FasTCAR next-day manufacturing platform. In addition to the ELMM study, GC012F is being evaluated in an ongoing Phase 1b/2 U.S. IND study for the treatment of relapsed/refractory multiple myeloma (RRMM) and in a Phase 1/2 clinical trial for the treatment of refractory systemic lupus erythematosus (rSLE) that will initiate in 2024. GC012F is also being evaluated in four investigator-initiated trials (IIT) for the treatment of rSLE, RRMM, newly-diagnosed multiple myeloma (NDMM) and B-cell non-Hodgkin lymphoma (B-NHL). Updated clinical results from the NDMM IIT presented at the 65th American Society of Hematology Annual Meeting & Exposition in December 2023, showed GC012F demonstrated an overall response rate of 100% and minimum residual disease negative stringent complete response rate of 95.5%.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.19%
Tags
clinical trial
Rhea-AI Summary
AstraZeneca (NASDAQ: GRCL) to acquire Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company developing innovative cell therapies for cancer and autoimmune diseases. The acquisition will enrich AstraZeneca's pipeline with a novel, clinical-stage FasTCAR-enabled BCMA and CD19 dual-targeting autologous chimeric antigen receptor T-cell (CAR-T) therapy, GC012F, with a transaction value of approximately $1.2bn.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.32%
Tags
acquisition
-
Rhea-AI Summary
AstraZeneca (NASDAQ: GRCL) to acquire Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company developing innovative cell therapies for cancer and autoimmune diseases. The acquisition will enrich AstraZeneca's pipeline with a novel, clinical-stage FasTCAR-enabled BCMA and CD19 dual-targeting autologous chimeric antigen receptor T-cell (CAR-T) therapy, GC012F, with a transaction value of approximately $1.2bn.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
60.26%
Tags
acquisition
-
Rhea-AI Summary
AstraZeneca (NASDAQ: GRCL) to acquire Gracell Biotechnologies Inc. for a total transaction value of up to $1.2 billion, enriching its cell therapy pipeline with GC012F, a clinical-stage autologous BCMA/CD19 CAR-T therapy targeting haematologic malignancies and autoimmune diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
60.26%
Tags
acquisition
Rhea-AI Summary
Gracell Biotechnologies Inc. (NASDAQ: GRCL) expands clinical development of GC012F in rSLE following FDA IND clearance for Phase 1/2 trial in the United States
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.79%
Tags
clinical trial
-
Rhea-AI Summary
Gracell Biotechnologies Inc. (NASDAQ: GRCL) presented updated results from the clinical investigator-initiated trial of GC012F for treatment of newly diagnosed multiple myeloma at the 65th ASH Annual Meeting. GC012F demonstrated a 100% overall response rate and 95% MRD- stringent complete response rate among 22 transplant-eligible, high-risk NDMM patients. The therapy also showed a favorable safety profile with no new safety signals observed.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.09%
Tags
clinical trial
-
Rhea-AI Summary
Gracell Biotechnologies Inc. (GRCL) has received FDA clearance for its Investigational New Drug (IND) application to initiate a Phase 1/2 clinical trial of FasTCAR-T GC012F, a dual-targeted CAR-T cell therapy, for the treatment of refractory systemic lupus erythematosus (rSLE) in the United States. The therapy has shown deep responses and a favorable safety profile in clinical investigator-initiated trials. GC012F aims to provide a transformative therapy for SLE patients, addressing the urgent need for highly effective and safe treatment options.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.93%
Tags
clinical trial
Rhea-AI Summary
Gracell Biotechnologies Inc. (NASDAQ: GRCL) will present at the Cell Therapy for Autoimmune Disease Summit to discuss the application of next-generation CAR-T cell therapy technologies for the treatment of autoimmune disease, focusing on the development of FasTCAR-enabled CD19/BCMA dual-targeting GC012F in systemic lupus erythematosus (SLE). Dr. Samuel Zhang, Chief Business Officer, will present on Nov. 28 at 5 pm ET in Philadelphia and online.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.07%
Tags
conferences
Gracell Biotechnologies Inc

Nasdaq:GRCL

GRCL Rankings

GRCL Stock Data

989.87M
165.04M
16.39%
63.11%
1.23%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
China
Suzhou

About GRCL

gracell biotechnologies inc. is a global clinical-stage biopharmaceutical company dedicated to discovering and developing breakthrough cell therapies. leveraging its pioneering fastcar and truucar technology platforms, gracell is developing a rich clinical-stage pipeline of multiple autologous and allogeneic product candidates with the potential to overcome major industry challenges that persist with conventional car-t therapies, including lengthy manufacturing time, suboptimal production quality, high therapy cost and lack of effective car-t therapies for solid tumors.